Bibliographic information
Recommendation
In hospitalized children aged 0–18 who meet a standard case definition for multisystem inflammatory syndrome (MIS-C) and diagnostic criteria for Kawasaki disease, we suggest using corticosteroids in addition to standard of care for Kawasaki disease
Recommended in favor
Conditional
Certainty of evidence
Very low
Notes and Remarks
Practical Info There are slightly different case definitions for MIS-C (Annex 5). This guideline is applicable for any standard case definition of MISC. Case definitions will continue to be updated as new data emerge. Based on accessibility to corticosteroids being much wider than accessibility to IVIG, the panel suggested that most patients will receive corticosteroids before they receive IVIG, even in patients where both are prescribed. Route: Systemic corticosteroids can be given orally or intravenously. All studies examined intravenous administration. Dose and duration: In the three studies included in the meta-analysis, intravenous methylprednisilone was used at varying doses; one study did not report a dose. The other two reported ranges between 0.8–2.0 mg/kg/day for 5 days; or higher bolus doses of 10–30 mg/kg/day for 3 days. Both lower and higher dose options can be considered. See Annex 4 for study details. Monitoring: It would be prudent to monitor for known complications associated with corticosteroid use, such as hyperglycemia and behavioural changes. Supportive care: Most emphatically, the GDG emphasized the importance of high-quality supportive care to improve the outcomes of these children, apart from specific therapies. Please see the WHO Pocket Book of Hospital Care for Children for syndromic management guidance of severely ill children, including the importance of recognizing other conditions such leading to shock, sepsis and severe infections; as well as guidance from other organizations on supportive management of Kawasaki disease (81). Uncertainties The GDG emphasized the need for further randomized clinical trials in this population with these agents. The panel acknowledged that results of ongoing randomized trials of therapeutic interventions for MIS-C over the next several months were highly likely to upgrade the certainty of evidence and may lead to changes in recommendations. Enrolment of patients into randomized trials should be prioritized.
Important considerations Corticosteroids are widely available in all regions of the world and methylprednisolone is on the WHO Model List of Essential Medicines. IVIG has important resource considerations, including higher cost, and is not readily available across all care settings and regions.
Also Featured In
This recommendation also appears in the following guidelines:
Living guidance for clinical management of COVID-19: living guidance, 23 November 2021.
Clinical management of COVID-19: living guideline, 23 June 2022.
Clinical management of COVID-19: living guideline, 15 September 2022.
Clinical management of COVID-19: living guideline, 18 August 2023
Clinical management of COVID-19: living guideline, June 2025